MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles

Abstract

Dysregulated microRNAs (miRNAs) have been reported to be associated with pancreatic cancer (PaC), suggesting that they may serve as useful novel diagnostic biomarkers for PaC. Various studies have been performed to investigate the diagnostic value of miRNAs for PaC but have obtained conflicting results. Therefore, this meta-analysis aims to comprehensively and quantitatively evaluate the potential diagnostic value of miRNAs for PaC. We systematically searched PubMed, Embase, Google Scholar, Cochrane Library, and Chinese National Knowledge Infrastructure for publications concerning the diagnostic value of miRNAs for PaC without language restriction. The quality of each study was scored using the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). The summary receiver operator characteristic curve and other parameters were applied to check the overall test performance. Heterogeneity was tested with the I (2) test and publication bias was tested with the Deek's funnel plot asymmetry test. This meta-analysis included 18 articles with a total of 2,036 patients and 1,444 controls. The pooled sensitivity was 82 % (95 % CI, 78-86 %); the specificity was 77 % (95 % CI, 73-81 %); the PLR was 3.6 (95 % CI, 3.0-4.4); the NLR was 0.23 (95 % CI, 0.18-0.29); the DOR was 16 (95 % CI, 10-24); and the AUC was 0.86 (95 % CI, 0.83-0.89). Subgroups analyses were also performed and revealed that there were significant differences between some subgroups: the multiple-miRNAs profiling-based assays, non-blood-based assays, and healthy control-based studies all showed higher accuracies in diagnosing PaC than that of their counterparts. This meta-analysis suggests that the use of miRNAs has potential diagnostic value with a relatively high sensitivity and specificity for PaC, particularly the use of multiple miRNAs for discriminating PaC patients from healthy individuals. More prospective studies on the diagnostic value of miRNAs for PaC are needed in the future.

Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles

“…When stratified by sample types, the results indicate that comparing to urine-based assays, blood-based assays could be a better choice as a diagnostic tool. Ding et al carried out a meta-analysis to evaluate the diagnostic value of miRNAs for pancreatic cancer and made a similar observation that blood-based assays were significantly better than non-blood-based assays [ 37 ]. However, Wei et al performed a meta-analysis to measure the diagnostic value of miRNAs for cancers of the central nervous system and found that cerebrospinal fluid-based assays had more precise results than blood-based assays [ 38 ].…”

Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer

“…However, it was observed only in few samples, therefore, further validation of miR-196a and -196b should be carried out to test their utility in PC diagnosis [230]. A meta-analysis study was carried out on 18 articles with a total of 2,036 patients and 1,444 controls to determine the role miRNAs in early diagnosis and reported that pooled sensitivity of 82 % (95 % CI, 78–86 %); and specificity of 77 % (95 % CI, 73–81 %) with AUC of 0.86 (95 % CI, 0.83–0.89), suggesting the potential diagnostic value of miRNAs (inclusion of multiple miRNAs for diagnosis) to discriminate PC patients from healthy controls with high sensitivity and specificity [231]. …”

MicroRNA‐410 functions as a tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic cancer

“…Generally, tumor‐suppressive miRNAs are often downregulated in a range of cancers , whereas oncogenic miRNAs are upregulated . Some miRNAs are dysregulated in pancreatic cancer and function as novel biomarkers for diagnosis and potential therapeutic targets . However, the roles of miR‐410 in tumorigenesis of pancreatic cancer remain poorly understood.…”